Compare Consolidated Edison, Inc. (ED) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs Novo Nordisk A/S — how do they compare? Consolidated Edison, Inc. trades at $106.11 (market cap $38.70B), while Novo Nordisk A/S trades at $37.99 (market cap $168.73B). The key difference: Novo Nordisk A/S is far larger — about 4.4× Consolidated Edison, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (4.7%). Which is the better fit depends on your goals — on Pluang, investors hold Consolidated Edison, Inc. for 75 Days and Novo Nordisk A/S for 116 Days on average.
| ED | NVO | |
|---|---|---|
Market Cap | $38.70B | $168.73B |
Volume | 2,154,810 | 13,531,267 |
Sector | Utilities | Health |
52-Week High | $115.46 | $63.98 |
52-Week Low | $95.37 | $35.29 |
Typical Hold Time | 75 Days | 116 Days |
Enterprise Value | $65.55B | $183.05B |
Dividend Yield | 3.36% | 4.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ED (Consolidated Edison) trades at $105.99, up 0.83% today, near the consensus price target of $106.33. The stock shows a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, 2025 revenue grew to $16.92B with a net income margin of 12.53%, while recent earnings have been mixed with a Q1 2026 miss. The company maintains a solid dividend, with a recent $0.89 payout announced for September 2026, and is highlighted in news for its economic impact in New York and involvement in electric bus infrastructure.
Outlook is balanced; ED offers stability as a utility stock with consistent dividends and moderate growth, but faces risks from debt levels and interest expenses. Analyst sentiment is cautious with 62.96% hold ratings. Key catalysts include the upcoming investor presentation on October 6, 2026, and execution on capital investments. Risks involve regulatory changes and economic sensitivity.
Novo Nordisk (NVO) trades at $38.18, up 1.73% with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat estimates, with Q2 2026 EPS of $0.96 surpassing the $0.82 expectation. The company maintains robust cash flow generation of $119.1B from operations in 2025.
NVO presents compelling value with a 9.71 P/E ratio and 16.8% upside to the $44.67 consensus target. Key risks include FDA regulatory delays for hemophilia drug denecimig and intensifying competition from Eli Lilly in obesity treatments. The bullish analyst consensus (59% buy ratings) supports the growth outlook despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
